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Background: In our previous studies conducted on Ardisia crispa roots, it was shown that Ardisia crispa root
inhibited inflammation-induced angiogenesis in vivo. The present study was conducted to identify whether the
anti-angiogenic properties of Ardisia crispa roots was partly due to either cyclooxygenase (COX) or/and lipoxygenase
(LOX) activity inhibition in separate in vitro studies.
Methods: Benzoquinonoid fraction (BQ) was isolated from hexane extract by column chromatography, and later
analyzed by using gas chromatography–mass spectrometry (GC-MS). Anti-angiogenic effect was studied on mouse
sponge implantation assay. Ardisia crispa ethanolic rich fraction (ACRH), quinone-rich fraction (QRF) and BQ were
screened for COX assay to evaluate their selectivity towards two isoforms (COX-1 and COX-2), The experiment on
soy lipoxygenase (LOX) inhibitory assay was also performed to determine the inhibitory effect of ACRH, QRF and BQ
on soy LOX.
Results: BQ was confirmed to consist of 2-methoxy-6-undecyl-1,4-benzoquinone, when compared with previous
data. Antiangiogenesis study exhibited a reduction of mean vascular density (MVD) in both ACRH and QRF,
compared to control. In vitro study showed that both ACRH and QRF inhibited both COX-1 and COX-2, despite
COX-2 inhibition being slightly higher than COX-1 in BQ. On the other hand, both ACRH and QRF were shown to
have poor LOX inhibitory activity, but not BQ.
Conclusions: In conclusion, ACRH and QRF might possibly exhibit its anti-angiogenic effect by inhibiting cyclooxygenase.
However, both of them were shown to possess poor LOX inhibitory activity. On the other hand, BQ displayed selectivity
to COX-2 inhibitory property as well as LOX inhibitory effect.
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Angiogenesis is a fundamental process of new capillary
formation which is physiologically important in wound
healing and reproduction [1]. Under normal physiologic
circumstances, the body controls angiogenesis by pro-
ducing a precise balance of pro-angiogenic and anti-
angiogenic factors [2]. The imbalance of these factors
will result in excessive or insufficient angiogenesis. Exces-
sive angiogenesis for instance, contributes to initiation,
progression, and prognosis of numerous diseases, such as
cancer, arthritis, and cardiovascular diseases [3].* Correspondence: roslida@medic.upm.edu.my
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distribution, and reproduction in any mediumCyclooxygenase (COX), also known as prostaglandin
endoperoxide synthase, is a rate-limiting enzyme that
catalyzes the transformation of arachidonic acid into
prostaglandin H2 (PGH2), which eventually leads to the
biosynthesis of other prostanoids (i.e. prostaglandins,
prostacyclin and thromboxane) [4]. There are two iso-
zymes identified in the COX family, which are COX-1 and
COX-2. Whilst the COX-1 expression is constitutive in
most tissue and exhibit physiological roles in the body,
COX-2 expression is inducible upon a wide spectrum of
stimuli, such as inflammatory responses [5].
Whilst COX-2 is important in catalyzing prostaglandin
biosynthesis during inflammation, it also contributes to
angiogenesis by upregulating VEGF level [6]. COX-2 is
shown to be induced not only in the endothelial cellsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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vasculatures [7]. Since COX-2 level is shown to be upreg-
ulated in preneoplastic condition as well as early cancer, it
is suggested that COX-2 inhibition may prevent carcino-
genic progression at several stages [8].
Meanwhile, lipoxygenase (LOX) converts arachidonic
acid into various leukotrienes that play an important role
in inflammation [9]. LOX involvement in angiogenesis is
evident. For instance, 5-lipoxygenase (5-LOX) product,
namely 5-HETE and LTA4, potently upregulate VEGF
transcription in human malignant mesethelioma model
[10]. Apart from that, since VEGF is a potent pro-
angiogenic factor, 5-LOX was shown to promote in vivo
tumour development by a direct proliferative stimulus
on cancer cells and a potentiation of the pro-angiogenic
response by the host stromal cells. 5-LOX products were
also demonstrated to upregulate VEGF transcription in
human umbilical vein endothelial cells [10]. Lipoxygen-
ase metabolites were shown to enhance tumourigenesis,
thus implying that the intervention through this pathway
might be useful in arresting cancer progression [11].
Ardisia crispa has been reported in previous studies
to exhibit anti- metastatic [12], anti-inflammatory, anti-
hyperalgesic [13] and antiangiogenic [14] properties in vivo.
Preliminary phytochemical studies conducted on Ardisia
crispa reported the isolation of compounds such as triter-
penoid saponins [15], and benzoquinones [12,16], which
were shown to exert various properties including the
aforementioned activities in vivo. This study aims to con-
firm the antiangiogenic activities exhibited by ACRH and
QRF, and investigate whether the angiogenic activities




Gelatine from cold fish, agarose, DMSO, phosphate-
buffered saline (PBS) (Sigma Aldrich, USA), licofelone
(Cayman, USA), gelatine sponge (Pharmacia and Upjohn,
USA), histosec pastilles (Merck, Germany), Hematoxylin
and Eosin (Merck, Germany), formalin (Merck, Germany),
nylon suture 16 mm (Unik, USA), Burnolplus® (Reckitt
Benckiser, USA), high profile microtome blade (Leica
Microsystems, USA), coverslip (Hirschmann Laborgerate,
Germany), DPX (BDH, USA), Colorimetric COX (ovine)
Inhibitor Screening Assay Kit (No. 760111) (Cayman,
USA), Soybean lipoxygenase type I-B, Linoleic acid, So-
dium phosphate monobasic, Sodium phosphate dibasic
(Sigma Aldrich, USA). All other reagents were of analyt-
ical grades and are therefore available commercially.
Plant material
Ardisia crispa roots (ACR) was collected in Machang,
Kelantam and identified by Dr. Roslida Abdul Hamid(Universiti Putra Malaysia). Ardisia crispa roots (ACR) with
voucher specimen 20841 from Herbarium of Universiti
Kebangsaan Malaysia was dried in an oven at 60°C for
5 days (Memmert, Germany) and grinded to form powder
(Retsch, Germany). Soon after, ACR was extracted using
80% EtOH (v/v; 2000 mL × 3, 48 hr each) and fractionated
using n-hexane (2000 mL × 3, 48 hr each), to yield Ardisia
crispa roots ethanolic hexane fraction (ACRH), as pro-
posed previously [17].
Separation and isolation of benzoquinonoid fraction (BQ)
ACRH (6 g) was later separated by silica gel column
chromatography using n-hexane and progressing to n-
hexane/ethyl acetate (from 10:0 to 5:5, v/v) to give five
fractions A-E. Fraction C and D (obtained from the mo-
bile phase of n-hexane: EtOAc at 7:3 and 6:4) were pooled
together, labelled as CD and was further rechromato-
graphed with the same solvent system of n-hexane/EtOAc
(from 9:1 to 5:5) to afford five subfractions CD1-CD5.
Subfractions CD3 and CD4 were combined together, to
yield a quinone rich fraction (QRF) (38.33%, w/w), which
was compared with the reference, AC-2 [18] at the similar
spots (Rf: 0.76) using thin layer chromatography (TLC)
technique, with chloroform as its developing system.
QRF was re-chromatographed using similar gradient of
elution, hexane-EtOAc (10:0 to 6:4, 500 ml, v/v), affording
four major sub-fractions. Among the four sub-fractions,
vials 76–85 were shown to contain the most concentrated
yellowish spot, which shared similar spot as the reference
(Rf: 0.76). Therefore, the fractions contained in vials 76
to 85 were pooled, and purified by washing the fraction
with hexane to eliminate excess oil and debris. Re-
chromatography using glass pipette was done two times
using similar gradient of mobile phase (9:1 to 6:4; 10 ml,
v/v) to yield approximately 107.4 mg of fraction labelled
as benzoquinonoid fraction (BQ) (1.79%, w/w). BQ was
characterized as a dark yellow amorphous powder. It
was further resolved in GC-MS for the identification
purpose. A flow chart portraying fractionation process
and its yield was summarized in Figure 1.
Experimental animals
Male ICR mice (25-30 g) at 6–8 weeks of age were used
with each cage accommodated 6 mice in a standard la-
boratory condition (temperature 25 ± 2°C, and 12-hour
light and dark cycle). The animals had access to water and
food pellet ad libitum. Ethical clearance was obtained from
the Animal Care and Use Committee (ACUC), Faculty of
Medicine and Health Sciences, Universiti Putra Malaysia,
Malaysia (Reference number: UPM/FPSK/PADS/UUH/F05).
Mouse sponge implantation assay
This study was carried out according to previously pro-
posed method [19]. Prior to experimentation, absorbable
Figure 1 TLC-guided chromatographic isolation of BQ from Ardisia crispa root.
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sterile PBS overnight at 4°C. Approximately 100 μl of 0.4%
agarose was mixed with 50 μl of VEGF (2 ng/μl) and 50 μl
of treatments (licofelone, ACRH or QRF) (2 ng/μl) or
DMSO 1% (vehicle). The sponges were allowed to solidify
at room temperature for one hour before commencement
of the experiment. Mice were anesthetized with Avertin
(10 mL/kg) prior to experimentation. Hardened gel piece
was inserted into incised subcutaneous pocket createdlaterally. The animals were allowed to recuperate for
14 days. After that, the animals were euthanized and the
gel piece was harvested and rinsed with normal saline.Histopathological evaluation
The sponge samples were fixed in 10% formalin (v/v)
for 7 days and subjected to histopathological analysis.
The number of vessels was counted in 15 consecutive
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culated [19].
Cyclooxygenase inhibitory assay
Cyclooxygenase activity assay was performed according
to Yang et al. [20], with slight modification. Inhibitory
activity of ACRH, QRF and BQ towards COX-1 and
COX-2 activity was determined by using colorimetric
COX (ovine) inhibitor screening assay kit (Cayman, No.
760111). The assay was conducted by monitoring the
appearance of oxidized N, N, N’, N’- tetramethyl-p-
phenediamine (TMPD) at 590 mm. Aspirin served as
positive control [20]. The test compounds were dissolved
in 1% DMSO (v/v) at 5 different concentrations, which
were 12.5, 25, 50, 100 and 200 μg/mL. The experiment
was done in accordance to the one recommended by the
supplier. The plate was shaken for a few seconds and in-
cubated for 5 min at 25°C. 20 μl of the colorimetric sub-
strate solution (TMPD) was added to all of the wells. 20 μl
of arachidonic acid was added to all the wells. The plate
was shaken for a few seconds and incubated for 5 min at
25°C. The absorbance was measured at 590 nm using a
microplate reader. Average absorbance was calculated for
all the samples (n = 3) in order to determine the percent-
age of inhibition. The calculation of inhibitory percentage
is as portrayed below:
% inhibition ¼ 100% initial activity‐inhibitor wellsð Þ
100% initial activity
 100
Soy lipoxygenase inhibitory assay
Soy lipoxygenase inhibitory assay was performed accord-
ing to the method proposed by Azhar-Ul-Haq et al. [21].
Rutin was used as positive control [22]. 160 μl of 100 mM
sodium phosphate buffer (pH8.0), 10 μl of ACRH and
QRF were dissolved in ethanol in different concentrations
(200 μg/mL, 100 μg/mL, 50 μg/mL, 25 μg/mL, and
12.5 μg/mL) and 20 μl of lipoxygenase solution were
mixed in the well and incubated for 10 mins at room
temperature. The reaction was then initiated by adding
10 μl of linoleic solution and the absorbance was deter-
mined at 234 nm after 6 minutes. All concentrations
were performed in triplicate. The IC50 value was then
calculated.
Statistical analysis
In mouse sponge implantation assay, statistical analysis
was performed using SPSS version 16. One-way Analysis
of Variance (ANOVA) with post-hoc test of Least Sig-
nificant Difference (LSD) were utilised with P < 0.05 was
considered to be statistically significant. The results were
reported as mean ± SEM. For in vitro studies, average ofthe results obtained was determined in order to construct
a graph, whereby IC50 of each groups were identified, re-
spectively. IC50 was calculated using GraphPad Prism 5
software. Data were reported as mean ± SEM.
Results and discussions
Extraction and separation of quinone rich fraction (QRF)
and benzoquinonoid fraction (BQ)
Approximately 500 g of Ardisia crispa root plant mater-
ial extraction yielded 21.01 g (25.87%, w/w) of Ardisia
crispa root hexane fraction (ACRH), characterized as a
brown-black oily mass. 6 g of ACRH was eluted through
a column to yield 2.3 g of QRF (38.38%, w/w), using
solvent hexane: ethyl acetate with ratio of 7:3 and 6:4
(500 mL; each mobile phase ratio). By using AC-2 (refer-
ence compound) as guidance in the TLC-guided fraction-
ation, refractionation of QRF was carried out to pool
benzoquinonoid fraction, yielding 107.4 mg of benzoqui-
nonoid compound (1.79%, w/w) with similar chemical
characterization as 2-methoxy-6-undecyl-1.4-benzoquin-
one [16], labeled as BQ. Isolating benzoquinone has been
the basis of the isolation protocol of this study, primarily
as unusual series of benzoquinones isolated from various
species of Ardisia crispa, such as Ardisia sieboldii [23]
and Ardisia japonica [18] were shown to possess anti-
inflammatory properties, and anti-inflammation is shown
to be strongly correlated to anti-angiogenesis [24].
Chromatographic analysis of BQ
In the present study, GC-MS method was employed to
confirm the nature of the AC-2 (reference) as a 1, 4-
benzoquinone derivative, specifically 2-methoxy-6-unde-
cyl-1, 4-benzoquinone, which was first isolated by Roslida
[16]. The gas chromatograms of BQ were depicted in
Additional file 1. One major peak (Peak 2), assumed to be
2-methoxy-6-undecyl-1,4-benzoquinone was shown at
39.54 min. Whilst, minor peaks at 35.51 (Peak 1), 41.79
(Peak 3) and 49.92 min were also displayed in the
spectrum. The major peak at 39.537 min was further re-
solved for mass spectrometry, and compared with the ref-
erence [16] (Additional file 2: a & b)
The molecular ion peak of chromatogram present at
min 39.537 for BQ was 292.1 [M+], with mass break
down also present at m/z 193.1, 179.1, 154, 124, and 69
(Additional file 2: a). Its molecular ion peak of the chro-
matogram present was consistent with that of previously
obtained in previous report (292.0 [M+]) (Additional file 2: b),
thus suggesting the compound identified as 2-methoxy-
6-undecyl-1,4-benzoquinone.
Mouse sponge implantation method
Rat air pouch [25] and Miles assay [26] were previously
used to quantify angiogenesis and evaluate anti-angiogenic
agents of ACRH and QRF in vivo [14]. The objective of
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factor into a suitable carrier such as sponge-like structure,
which will cause the recruitment of new blood vessels into
implant. The increase of number of blood vessels present
in the sponge, which originally contained none, will repre-
sent neovascularisation [27]. VEGF was used as the angio-
genic factor as it is a potent vasculogenic agent [28]. This
assay offered some distinct advantages over conventional
angiogenic assays, such as biocompatibility and the feasi-
bility of studies conducted in a long term. Additionally,
grafts can be implanted in immunologically normal ro-
dents [19].
The anti-angiogenic effect of ACRH and QRF on mean
vascular density (MVD) was determined in the present
study. There was no significant difference in MVD of
VEGF control (VEGF alone) and vehicle control (VEGF
and DMSO), which also indicated DMSO as a vehicle
did not possess any significant blood vessel- reducing ac-
tivity in this study. However, treatment with licofelone
(100 ng), ACRH (100 ng), and QRF (100 ng) resulted in
a significant reduction in mean vascular density (MVD),
with the MVD value being 3.67 ± 0.843 (P < 0.01), 5.00 ±
0.894 (P < 0.05), 2.83 ± 0.833 (P < 0.01), respectively,
compared to VEGF control (7.76 ± 2.34). In addition,
there was no significant difference observed in ACRH
and QRF treatment group, compared to licofelone. The
MVD of the treatment of ACRH and QRF at similar dose
(100 ng), was also observed not to significantly differ as
well. Interestingly, QRF is shown to be more potent than
licofelone (Table 1).
High MVD would depict a dense blood vessels impreg-
nated in the gel, while low MVD would show sparse blood
vessels embedded in the gel. Histopathological slides of
the gel sections for different treatments showing forma-
tion of blood vessels were shown in Figure 2A-E. It was
noted that at 200× magnification, a dense blood vessels,
which was also reflected in the MVD count, was found in
the VEGF-impregnated gel and in VEGF-impregnated gel
with DMSO (Figure 2A, B). Meanwhile, in the group ofTable 1 Quantification of mean vascular density (MVD)
following various treatments in mouse sponge
implantation assay
Treatment Mean vascular density
(MVD) ± SEM
% inhibition
VEGF 11.17 ± 2.442 -
VEGF + 1% DMSO (vehicle) 7.76 ± 2.348 -
VEGF + licofelone 3.67 ± 0.843b 67.14
VEGF + ACRH 5.00 ± 0.894a 55.23
VEGF + QRF 2.83 ± 0.833b,A 74.66
Data were presented as Mean ± SEM. Values with different superscript letters
within the same column are statistically different aP < 0.05; bP < 0.01 compared
to control group (VEGF), while AP < 0.05 compared to control group (VEGF + 1%
DMSO), determined by one-way ANOVA and LSD post-hoc test.VEGF-embedded gel treated with licofelone, ACRH and
QRF, scanted blood vessels were observed in the histo-
logical slide (Figure 2C-E).
Cyclooxygenase inhibitory assay
Arachidonic acid is metabolized by cyclooxygenase and
lipoxygenase pathways to form mediators such as pros-
taglandins and leukotrienes with significant roles in in-
flammatory response [29]. COX-2 and COX-2- derived
prostaglandins have a significant role in angiogenesis in
such a way that COX-2 antagonists have the ability to
block neovascularisation [30]. In the present study, the
inhibitory effects of ACRH, QRF and BQ to both COX
isoforms (COX-1 and COX-2) were evaluated in vitro.
Aspirin, a non-selective cyclooxygenase inhibitor was
shown to inhibit both COX-1 and COX-2 competitively,
which was consistent a previous study [20]. Among all
NSAIDs, aspirin is a unique non-selective irreversible
COX inhibitor due to its ability to acetylate the Ser530
hydroxyl group in the primary active site of COX-1 and
COX-2 [31]. Celecoxib, a known selective COX-2 in-
hibitor, was shown have a good selectivity towards in-
hibition of COX-2 instead of COX-1. Celecoxib was
introduced as a highly selective COX-2 inhibitor and is
known as a remarkable anti-inflammatory drug with
lower gastrointestinal complication [32]. In contrast,
ACRH and QRF were shown to inhibit both COX-1 and
COX-2 competitively; though COX-2 inhibition was
slightly prominent. Interestingly, BQ was shown to pos-
sess selectivity towards COX-2 inhibition, and the action
was comparable to celecoxib. The anti-angiogenic effect
of ACRH and QRF could be partially explained by the po-
tent inhibitory effect of compounds consisted in both
ACRH and QRF on arachidonic metabolism through
COX-2 pathway; though it is shown that both ACRH and
QRF non-selectively inhibit COX-1 as well. It is also pos-
sible that BQ, which is a major chemical constituent of
ACRH and QRF [14,16], is responsible in exerting the
anti-angiogenic effect, mainly via COX-2 inhibition, based
on the present data obtained.
ACRH and QRF were assessed in vitro to investigate
their possible effects in COX activity inhibition. Percent-
age of inhibition of both isoforms of COX (COX-1 and
COX-2) was found to be dose-dependent. Aspirin was
shown to be the most effective COX-2 inhibitor with the
lowest IC50 (26.69 ± 2.245 μg/mL), followed by celecoxib
(29.10 ± 1.878 μg/mL), ACRH (37.79 ± 1.843 μg/mL) and
QRF (35.24 ± 1.958) respectively. Aspirin displayed non-
selectivity towards COX by inhibiting both isoforms
competitively.
Meanwhile, celecoxib displayed more selectivity to-
wards COX-2 than COX-1 with approximately 2-fold
percentage of inhibition increase, notably in the concen-





Figure 2 Microphotograph of sections showing blood vessels around gels impregnated with (A) VEGF; (B) VEGF and DMSO; (C) VEGF
and licofelone; (D) VEGF and ACRH; (E) VEGF and QRF. Red arrows indicated the blood vessels (Magnification 200×).




Aspirin 43.93 ± 1.471 26.69 ± 2.245
Celecoxib 44.21 ± 2.757 29.10 ± 1.878
ACRH 29.57 ± 2.188 37.79 ± 1.843
QRF 21.44 ± 7.533 35.24 ± 1.958
fAC2 (Rich AC-2) 51.48 ± 2.599 33.00 ± 2.010
IC50 was reported as IC50 ± SEM with COX inhibitory effects determined in the
concentration of 12.5, 25, 50, 100, and 200 μg/ml of each treatments priorly.
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play specific selectivity towards COX-2 inhibition. Both
COX-1 and COX-2 were inhibited competitively, though
COX-2 inhibition was more prominent, especially in
high concentration (100 μg/mL and above). The pattern
of COX-1 and COX-2 inhibition in ACRH and QRF was
comparable to aspirin. However, BQ showed preference
to COX-2 inhibition, with a 2.1-fold inhibition of COX-2
compared to inhibition of COX-1. The result was com-
parable to that of celecoxib. IC50 of both COX-1 and
COX-2 following treatments were shown in Table 2. The
percentage of inhibitions of COX isoforms following
various treatments were also tabulated in Table 3.
Soy lipoxygenase inhibitory assay
The use of soybean lipoxygenase in the in vitro inhibition
study served as an appropriate model for the screening of
plants with anti-inflammatory properties [31], as lipoxy-
genase found in plant was considered equivalent of theangiogenic cascades in animals [22]. ACRH and QRF did
not display significant LOX inhibitory activity. The finding
was in contrast with previous literature, as ACRH and
QRF were shown to have anti-oxidant activities (unpub-
lished data), and anti-oxidants were known to inhibit plant
lipoxygenases [32]. Meanwhile, BQ displayed LOX
Table 3 Percentage of inhibitions of COX-1 and COX-2 following treatments
Concentration
(μg/ml)
Percentage of COX inhibition (%)
COX-1 COX-2
12.5 25 50 100 200 12.5 25 50 100 200
Aspirin 27.778 ± 0.505 36.027 ± 1.347 37.879 ± 0.842 40.067 ± 1.347 46.465 ± 0.505 33.896 ± 1.074 51.380 ± 0.154 54.294 ± 0.307 59.049 ± 0.153 62.423 ± 0.154
Celecoxib 21.212 ± 1.010 23.569 ± 1.347 27.441 ± 1.852 31.818 ± 2.189 32.492 ± 1.179 25.920 ± 0.460 48.160 ± 0.614 52.454 ± 0.614 55.675 ± 1.074 63.650 ± 0.767
ACRH 26.094 ± 0.505 32.492 ± 0.505 34.512 ± 0.169 37.037 ± 0.000 38.215 ± 0.505 25.767 ± 1.534 38.037 ± 0.920 45.399 ± 0.614 49.693 ± 1.227 56.595 ± 0.153
QRF 25.589 ± 3.367 34.848 ± 0.506 35.690 ± 0.674 36.869 ± 2.189 37.710 ± 0.674 29.908 ± 0.460 41.258 ± 0.460 49.693 ± 0.000 51.687 ± 0.460 58.129 ± 0.154
BQ 20.707 ± 0.505 21.380 ± 0.169 25.253 ± 0.337 27.273 ± 0.337 29.125 ± 0.169 27.301 ± 0.000 43.558 ± 1.688 49.233 ± 0.154 57.209 ± 0.921 61.350 ± 1.277





























Table 4 IC50 of different treatments in soy LOX inhibitory
assay
Treatment Lipoxygenase assay (IC50)
(μg/ml)
Rutin 44.37 ± 2.65
Aspirin 137.4 ± 52.30
ACRH 304.5 ± 0.32
QRF 95.86 ± 2.17
BQ 66.65 ± 2.71
IC50 was reported as IC50 ± SEM with LOX inhibitory effects determined in the
concentration of 12.5, 25, 50, 100, and 200 μg/ml of each treatments priorly.
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dependent. Other than 1, 4-benzoquinone compound of
Ardisia crispa roots shown in the present study, there
are also several other 1, 4- benzoquinones isolated from
other Ardisia species possessing potent 5-lipoxygenase
inhibitory activity which were reported in previous stud-
ies, such as Ardisiaquinone A, isolated from Ardisia sie-
boldii [23], and Ardisianones A and B, isolated from
Ardisia japonica [33]. Ardisiaquinone A for instance, was
shown to decrease allergen-induced vascular permeability
significantly in guinea pigs [34].
LOX-suppressive effect of ACRH, rich fraction and
BQ were assessed in vitro. The inhibitory effect of soy
lipoxygenase was found to be prominent in rutin (IC50:
44.37 ± 2.65 μg/mL). ACRH showed minimum LOX in-
hibition, with IC50 of 304.5 ± 0.32 μg/mL. Apart from
that, QRF was also shown to be a weak inhibitor of
LOX, with IC50 being 95.86 ± 2.17 μg/mL. BQ was
found to be a moderate LOX inhibitor, with IC50 was
found to be 66.65 ± 2.71 μg/mL. The IC50 of each treat-
ment was depicted in Table 4. Meanwhile, the percentage
of inhibition of soy lipoxygenase following different treat-
ments was displayed in Figure 2.
Nonetheless, since angiogenesis is a multi-cellular event,
it is important to further confirm anti-angiogenic activities
of ACRH and QRF utilising various in vitro and in vivo
models that include other prominent features of angiogen-
esis such as the endothelial proliferation, migration and
tube formation [35]. Apart from that, the role of BQ spe-
cifically in eliciting COX-2 and LOX inhibitory responses
in both in vitro and in vivo angiogenic models can be fur-
ther elucidated, as it might become useful in the design of
new drug which targets converging pathway of COX-2
and LOX.
Conclusions
Taking the results together, it is confirmed that ACRH
and QRF exhibited antiangiogenic properties by signifi-
cantly reduce blood vessel formation, and it is possible
that the mechanism of blood vessel reduction is partly
mediated by non-selective inhibition of cyclooxygenasepathway. Through the COX and LOX inhibitory assays
conducted, it is demonstrated that BQ exhibited promising
inhibitory activities of selective COX-2 and LOX.
Additional files
Additional file 1: Gas chromatogram of BQ separated using gas
chromatography technique.
Additional file 2: Mass-spectrum of (a) major compound in BQ at
Rt=39.537, and (b) the reference, 2-methoxy-6-undecyl-1,
4-benzoqunone [23].
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
DEZAH performed the research and wrote the manuscript. RAH contributed
to the experimental design, data interpretation, editing and submission of
the manuscript. LSY contributed to the experimental design and data
interpretation. CNMT contributed to the experimental design. YLT performed
part of the research and its data interpretation. All authors read and
approved the final manuscript.
Acknowledgements
The study is funded by the Fundamental Research Grant Scheme (FRGS),
from the Ministry of Higher Education, Malaysia (Project no: 02-11-08-616FR).
The authors are thankful to the Faculty of Medicine and Health Sciences,
Universiti Putra Malaysia for providing necessary facilities.
Author details
1Department of Biomedical Science, Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor. 2Department of
Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia,
Serdang 43400, Selangor. 3Department of Paraclinical Science, Faculty of
Medicine and Health Sciences, Universiti Malaysia Sarawak, Kuching 93150,
Sarawak.
Received: 22 July 2013 Accepted: 14 March 2014
Published: 19 March 2014
References
1. Liekens S, De Clercq E, Neyts J: Angiogenesis: regulators and clinical
applications. Biochem Pharmacol 2001, 61:253–270.
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 1996, 86:353–364.
3. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med
1971, 285:1182–1186.
4. Dubois RN, Abramsom SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA,
Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998,
12(12):1063–1073.
5. Crofford LJ: Rational Use of analgesic and antiinflammatory drugs. N Engl
J Med 2001, 345:1844–1846.
6. Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC: Cyclooxygenase
2 expression is associated with angiogenesis and lymph node metastasis in
human breast cancer. J Clin Pathol 2002, 55:429–434.
7. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and
therapy of cancer metastasis. Cell 1994, 79:185–188.
8. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as
anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl
Cancer Inst 2002, 94:252–266.
9. Steinhilber D: 5-Lipoxygenase: a target for antiinflammatory drugs
revisited. Curr Med Chem 1999, 6:71–85.
10. Romano M, Catalano A, Nutini M, D’Urbano E, Crescenzi C, Claria J, Libner R,
Davi G, Procopio A: 5-Lipoxygenase regulates malignant mesothelial cell
survival: involvement of vascular endothelial growth factor. FASEB J 2001,
15:2326–2336.
11. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS,
Fan HZ, Fischer SM, Lippman SM: The 15-lipoxygenase-1 product 13-S-
Awang Hamsin et al. BMC Complementary and Alternative Medicine 2014, 14:102 Page 9 of 9
http://www.biomedcentral.com/1472-6882/14/102hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce
apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 2003,
100(17):9968–9973.
12. Kang YH, Kim WH, Park MK, Han BH: Antimetastatic and antitumor effects
of benzoquinonoid AC7-1 from Ardisia crispa. Int J Cancer 2001,
93:736–740.
13. Roslida AH, Kim KH: Anti-inflammatory effect and anti-hyperalgesic effect
of Ardisia crispa Thunb D. C. Pharmacogn Mag 2008, 4:262–268.
14. Hamsin DE, Hamid RA, Yazan LS, Taib CN, Ting YL: The hexane fraction of
Ardisia crispa Thunb A.DC. root inhibits inflammation-induced angiogenesis.
BMC Complement Altern Med 2013, 13:5.
15. Jansakul C, Baumann H, Kenne L, Samuelsson G: Ardisiacrispin a and B,
Two utero-contracting saponins from ardisia crispa. Planta Med 1987,
53:45–49.
16. Roslida AH: Anti-Inflammatory And Analgesic Effects Of Ac-2 Isolated
From Ardisia Crispa Are Mediated Via Cox-2 Inhibition. In Phd Thesis.
Universiti Malaya, Kuala Lumpur, Malaysia: Physiology Department; 2004.
17. McCarty M, Baker C, Bucana C, Fidler I: Quantitative and qualitative in vivo
angiogenesis assay. Int J Oncol 2002, 21:5–102002.
18. Abourashed EA, El-Feraly S, Hufford CD: Carboxylic acid microbial metabolites
of the natural benzoquinone, Maesanin. J Nat Prod 1999, 62:714–716.
19. Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T:
Evaluation of the effect of Withania somnifera root extracts on cell cycle
and angiogenesis. J Ethnopharmacol 2006, 105:336–341.
20. Yang LK, Khoo-Beattie C, Goh KL, Chng BL, Yoganathan K, Lai YH, Butler MS:
Ardisiaquinones from Ardisia teysmanniana. Phytochemistry 2001,
58:1235–1238.
21. Azhar-Ul-Haq, Malik A, Anis I, Khan SB, Ahmed E, Ahmed Z, Nawaz SA,
Choudhary MI: Enzyme inhibiting lignans from Vitex negundo. Chem
Pharm Bull 2004, 52(11):1269–1272.
22. Akula US, Odhav B: In vitro 5-lipoxygenase inhibition of polyphenolic
antioxidants from undomesticated plants of South Africa. J Med Plant Res
2008, 2:207–212.
23. Fukuyama Y, Kiriyama Y, Kodama M, Iwaki H, Hosozawa S, Aki S: Total synthesis
of Ardisiaquinone A, a potent 5-lipoxygenase inhibitor, isolated from Ardisia
sieboldii, and degree of 5-lipoxygenase activity of its derivatives. Chem
Pharm Bull 1993, 43:2211–2213.
24. Jackson JR, Seed M, Kircher C, Willoughby DA, Winkler JD: The
codependence of angiogenesis and chronic inflammation. FASEB J 1997,
11:457–465.
25. Zhang J, Sun Y, Zhang JQ, Ramires FJ, Weber KT: Appearance and
regression of rat air pouch tissue. J Mol Cell Cardiol 1999,
31:1005–1013.
26. Pakhneshan P, Birsner AE, Adini I, Becker CM, D’Amato RJ: Differential
suppression of vascular permeability and corneal angiogenesis by
nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 2008,
49:3909–3913.
27. Ribatti D: Chicken chorioallantoic membrane angiogenesis model. Methods
Mol Biol 2012, 843:47–57.
28. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial
growth factor (VEGF) and its receptors. FASEB J 1999, 13(1):9–22.
29. Alitonou GA, Avlessi F, Sohounhloues DK, Agnaniet H, Bessiere JM, Menut C:
Investigations on the essential oil of Cymbopogon giganteus from Benin
for its potential use as an anti-inflammatory agent. Intl J Aromatherapy
2006, 16:37–41.
30. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA,
Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of
cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306–1311.
31. Awtry EH, Loscalzo J: Cardiovascular drugs: aspirin. Circulation 2000,
101:1206–1218.
32. Ammon HPT, Safayhi H, Mack T, Sabieraj J: Mechanism of antiinflammatory
actions of curcumine and boswellic acids. J Ethnopharmacol 1993,
38:105–112.33. Fukuyama Y, Kiriyama Y, Okino J, Kodama M, Iwaki H, Hosozawa S:
Naturally occurring 5-lipoxygenase inhibitor. II. Structures and
syntheses of ardisianones A and B, and maesanin, alkenyl-1,4-
benzoquinones from the rhizome of Ardisia japonica. Chem Pharm Bull
1993, 41:561–565.
34. Fukuishi N, Takada T, Fukuyama Y, Akagi M: Antiallergic effect of
Ardisiaquinone A; a potent 5-lipoxygenase inhibitor. Phytomedicine 2001,
8(6):460–464.
35. Hua H, Feng L, Zhang XP, Zhang LF, Jin J: Anti-angiogenic activity of
julibiroside J8, a natural product isolated from Albizia julibrissin.
Phytomedicine 2009, 16:703–711.
doi:10.1186/1472-6882-14-102
Cite this article as: Awang Hamsin et al.: Ardisia crispa roots inhibit
cyclooxygenase and suppress angiogenesis. BMC Complementary and
Alternative Medicine 2014 14:102.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
